FEB 27, 2019 6:07 PM PST

Anti-Inflammatory Meds without Side Effects, Please

WRITTEN BY: Nicholas Breehl

Drugs such as ibuprofen or aspirin that relieve pain and lower fever are among the most frequently used drugs worldwide. These medicines aid in mitigating inflammation. However, in spite of their indisputable effectiveness and frequent use, we do not yet fully understand the underlying mechanisms of these drugs. In addition, when these drugs are taken, serious side effects occur and again, the causes of which have also not been sufficiently clarified.

The research team led by pharmacists Dr. Jana Gerstmeier and Prof. Oliver Werz of the University of Jena has developed a cell model with which they can find answers to these questions. As the team's scientists report in the specialist publication, 'The FASEB Journal,' they have succeeded in clarifying the complex effect of active compounds that are administered on the formation of endogenous signaling substances in immune cells during an inflammatory reaction. In the future, this will make it possible to develop new active drugs with fewer side effects. Working groups from Harvard Medical School in Boston and the Karolinska Institute in Stockholm were also involved in the research work.

Inflammation occurs in two phases.

"Inflammation proceeds -- roughly speaking -- in two successive phases," explains Markus Werner, a doctoral student at the Chair of Pharmaceutical and Medical Chemistry of Jena University and first author of the study. During the initial phase, type 'M1' immune cells (macrophages) are active. They produce inflammatory messenger substances (prostaglandins and leukotrienes) from unsaturated fatty acids, which trigger typical symptoms such as fever and pain. After a few days, the second phase begins, in which the inflammation is resolved. In this phase, type 'M2' macrophages are active, which produce inflammation-resolving messenger substances from the fatty acids (called resolvins).

"Conventional drugs intervene equally in both phases," says Dr. Jana Gerstmeier. "They reduce the production of both proinflammatory messenger substances and inflammation-resolving mediators." This alleviates the first acute inflammatory reaction, but at the same time, it also hampers the second phase in which the inflammation resolves. "There is a risk of inflammation not being stopped and continuing to progress so that secondary diseases occur." Ideally, drugs should, therefore, reduce only the acute phase, but not impair the period in which the inflammation resolves.

The special feature of the methodology is its sensitivity

The newly developed cell model enables researchers to investigate the efficacy of drugs in both inflammatory phases. "For this purpose, we use human immune cells (M1 and M2), which we pre-treat with the drug to be tested before inducing an inflammatory reaction using pathogenic bacteria," explains Jana Gerstmeier. The messenger substances released by the cells are analyzed.

The distinctive feature of the methodology developed in Jena is its sensitivity: the inflammation-resolving substances of the second phase are useful in concentrations about 1,000 times lower than the inflammatory signal substances of the first inflammatory phase. Very sensitive analytics is required to be able to detect these substances, and the Jena laboratory is one of the few laboratories in the world to have mastered this methodology. Using a mass spectrometer, several dozen mediator molecules that have been released are detected, and an individual spectrum is created for each active ingredient. This allows conclusions to be drawn about the influence of the drug on the entire inflammatory process.

Sources: Science Daily, FASEB, YouTube

About the Author
You May Also Like
AUG 11, 2020
Drug Discovery & Development
Scientists Discover Key Gene Behind Antibiotic Resistance
AUG 11, 2020
Scientists Discover Key Gene Behind Antibiotic Resistance
Scientists from Oxford University have shown that a single gene can make some strains of Staphylococcus aureus (the bact ...
SEP 11, 2020
Immunology
Could a Drug for Cats Treat COVID?
SEP 11, 2020
Could a Drug for Cats Treat COVID?
Canadian researchers have discovered that a drug used to treat coronavirus infections in cats shows promise in helping C ...
OCT 14, 2020
Immunology
Self-Healing Microcapsules Make Promising Leukemia Vaccines
OCT 14, 2020
Self-Healing Microcapsules Make Promising Leukemia Vaccines
Leukemia is a cancer affecting tissues in the body that produce blood cells, including the bone marrow and the lymphatic ...
OCT 17, 2020
Cell & Molecular Biology
Fat Droplets in Cells Help the Immune System Fight Infection
OCT 17, 2020
Fat Droplets in Cells Help the Immune System Fight Infection
Scientists have found that our immune system has a surprising helper: droplets of fat that sit inside cells.
NOV 12, 2020
Immunology
The Enzyme That Keeps Viruses In Stealth Mode
NOV 12, 2020
The Enzyme That Keeps Viruses In Stealth Mode
Some viral infections just don’t go away. The hepatitis C virus, for instance, can result in life-long chronic inf ...
NOV 12, 2020
Health & Medicine
Measles Cases and Deaths Surge Worldwide
NOV 12, 2020
Measles Cases and Deaths Surge Worldwide
Today, the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC) released a stat ...
Loading Comments...